Icahn to FBN: "No Accountability at Amylin"

Carl Icahn is like a Navy Seal sharp-shooter: he takes precise aim at companies he feels are poorly run and then, when he's sure he's right on target, squeezes the trigger. Sometimes they fall and fall hard, but he says he's not out to make them whither and die... he wants then to thrive.

Take the case of Amylin Pharmaceuticals. It's a biotech company known for its Diabetes drug Byetta, but it's also known as a stock that's taken a major beating in the last year... down close to 70%. Icahn owns nearly 10% of the stock and so his voice is louder than the average shareholder. He wants major changes at the top, specifically at the board level.

In an exclusive phone interview today, I asked him all about Amylin, Biogen Idec---another company against which he's fighting a proxy battle----- along with Yahoo, which he says he bought "too high."  But oh, there's SO much more from him.  Check out the clips below.